ArticleJournal of clinical microbiology2008
Use of phenotypic and molecular serotype identification methods to characterize previously nonserotypeable group B streptococci.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Capsule typing and clonal relationships of group B streptococci isolated from male patients diagnosed with urinary tract infection.Folia microbiologica · 2025Article
- Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study.Infection · 2023Article
- Comparative Analysis of the Molecular Characteristics of Group BAnnals of laboratory medicine · 2023Article
- Population genetics of group BFrontiers in microbiology · 2023Article
- A Facile machine learning multi-classification model for Streptococcus agalactiae clonal complexes.Annals of clinical microbiology and antimicrobials · 2022Article
- Genetic diversity and antimicrobial resistance of invasive, noninvasive and colonizing group BAccess microbiology · 2022Article
- Population genomics of Group B Streptococcus reveals the genetics of neonatal disease onset and meningeal invasion.Nature communications · 2022Article
- Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005-2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Genomic characterisation of perinatal Western Australian Streptococcus agalactiae isolates.PloS one · 2019Article
- Prevalence, Risk Factors, and Serotype Distribution of Group B Streptococcus Colonization in HIV-Infected Pregnant Women Living in Belgium: A Prospective Cohort Study.Open forum infectious diseases · 2018Article
- Identification of Group B Streptococcus Capsule Type by Use of a Dual Phenotypic/Genotypic Assay.Journal of clinical microbiology · 2017Article
- Complete genome sequence of Streptococcus agalactiae strain GBS85147 serotype of type Ia isolated from human oropharynx.Standards in genomic sciences · 2016Article
- Genomic analysis reveals the molecular basis for capsule loss in the group B Streptococcus population.PloS one · 2015Article
- DNA microarray-based typing of Streptococcus agalactiae isolates.Journal of clinical microbiology · 2014Article
- Capsular gene typing of Streptococcus agalactiae compared to serotyping by latex agglutination.Journal of clinical microbiology · 2013Article
- Inhibition of IL-10 production by maternal antibodies against Group B Streptococcus GAPDH confers immunity to offspring by favoring neutrophil recruitment.PLoS pathogens · 2011Article
- Article
- Evidence for rare capsular switching in Streptococcus agalactiae.Journal of bacteriology · 2010Article
- Diversity of group B streptococcus serotypes causing urinary tract infection in adults.Journal of clinical microbiology · 2009Article
- Molecular epidemiology of Streptococcus agalactiae isolated from mastitis in Brazilian dairy herds.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among 1,762 isolates of Streptococcus agalactiae (group B streptococcus [GBS]), 207 (12%) initially nonserotypeable isolates were tested by improved conventional serotyping methods (Lancefield antigen extraction with 0.1 and 0.2 N HCl, latex agglutination assays, and use of antisera against all known serotypes [Ia, Ib, and II to IX]) and a molecular serotype identification system (multiplex PCR-based reverse line blot [mPCR/RLB] assays targeting serotype-specific sites in the region spanning cpsH to cpsM). Serotypes were assigned to 71 (34%) of the 207 isolates by using antisera and to 204 (98.5%) of them by mPCR/RLB. Sequencing of a portion of the cpsE-cpsF-cpsG region of 141 persistently nonserotypeable isolates and 1 with discrepant conventional and molecular serotyping results was attempted. Major mutations were identified in 34 isolates (24%), including 11 (8%) from which no amplicons were obtained and 23 (16%) with sequence variation compared with published sequences; of the latter, 21 (15%) were associated with amino acid changes. By contrast, mutations were identified in only 12 (2.3%) of 516 serotypeable isolates for which this region has been sequenced previously. In summary, an improved serotyping scheme allowed serotype identification of more than one-third of the previously nonserotypeable GBS isolates. Molecular serotypes were assigned to almost all of the isolates by mPCR/RLB. Significant mutations (with no amplicons or with associated amino acid changes) were found in the cpsE-cpsF-cspG region of a higher proportion of nonserotypeable than of serotypeable isolates (32/141 versus 8/516; P < 0.001), but further investigation is needed to determine the genetic basis for most nonserotypeable GBS isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.